Mercury Labs Stock Price Today (NSE: MERCURYLAB)
Fundamental Score
Mercury Labs Share Price Live NSE/BSE & Institutional Fundamental Analysis
Mercury Labs share price today is ₹850.55, up +0.00% on NSE/BSE as of 2 January 2026. Mercury Labs (MERCURYLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹102.07 (Cr). The 52-week high for MERCURYLAB share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 20.79x, MERCURYLAB is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 5.94% and a debt-to-equity ratio of 0.11.
Mercury Labs Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Mercury Labs Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Mercury Labs Share Price: A ROCE Efficiency Analysis
In the dynamic pharmaceutical sector, where innovation and regulatory navigation are paramount, efficient capital allocation is a critical determinant of long-term success. This analysis delves into the financial health of Mercury Labs, focusing particularly on its Return on Capital Employed (ROCE) efficiency. The current Mercury Labs share price stands at ₹850.55, accompanied by a Price-to-Earnings (PE) ratio of 20.79 and a ROCE of 8.94%.
The relatively low ROCE of 8.94% warrants careful consideration. ROCE measures how effectively a company is generating profits from its capital investments. While a higher ROCE generally indicates better efficiency, the specific benchmark varies across industries. A lower ROCE can suggest inefficiencies in capital deployment, higher operating costs, or challenges in generating sufficient returns on investments. This is a key aspect examined in our comprehensive analysis, verified by Sweta Mishra as part of an 80-parameter fundamental audit.
When evaluating Mercury Labs, it's important to compare it against its sector peers. For example,
Mankind Pharma Ltd often benefits from a perception of strong management quality, reflected in potentially different market valuations. Comparing management efficiency and strategic decisions across companies like Mankind Pharma Ltd, Smruthi Organics Ltd, and Balaxi Pharmaceuticals Ltd provides valuable context for understanding Mercury Labs' ROCE performance.The 8.94% ROCE has implications for the company's economic moat – its ability to sustain a competitive advantage. While product innovation and brand reputation can contribute to a moat, a consistently low ROCE may erode the company's ability to reinvest profits effectively and maintain its competitive edge. A higher ROCE enables a company to reinvest more aggressively, fund research and development, and potentially acquire smaller competitors, strengthening its market position. Our analysis seeks to determine if the current ROCE is sufficient for Mercury Labs to build and defend its market share. The information presented is purely observational and is not a recommendation to buy or sell the stock.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Mercury Labs Fundamental Analysis & Valuation Benchmarking
Educational evaluation of MERCURYLAB across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Attractive Valuation (P/E: 20.79 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (228.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Conservative Debt Levels (D/E: 0.11)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (13.17x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (73.66%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Below-Average Return on Equity (5.94%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (8.94%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Weak Earnings Growth (-0.82% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-0.82% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Mercury Labs Financial Statements
Comprehensive financial data for Mercury Labs including income statement, balance sheet and cash flow
About MERCURYLAB (Mercury Labs)
Mercury Labs (MERCURYLAB) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹102.07 (Cr). Mercury Labs has delivered a Return on Equity (ROE) of 5.94% and a ROCE of 8.94%. The debt-to-equity ratio stands at 0.11, reflecting the company's capital structure. Investors tracking MERCURYLAB share price can monitor key metrics including P/E ratio, promoter holding of 73.66%, and quarterly earnings growth.
Company Details
MERCURYLAB Share Price: Frequently Asked Questions
What is the current share price of Mercury Labs (MERCURYLAB)?
As of 02 Jan 2026, 03:49 pm IST, Mercury Labs share price is ₹850.55. The MERCURYLAB stock has a market capitalisation of ₹102.07 (Cr) on NSE/BSE.
Is MERCURYLAB share price Overvalued or Undervalued?
MERCURYLAB share price is currently trading at a P/E ratio of 20.79x, compared to the industry average of 31.77x. Based on this relative valuation, the Mercury Labs stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of MERCURYLAB share price?
The 52-week high of MERCURYLAB share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Mercury Labs share price?
Key factors influencing MERCURYLAB share price include quarterly earnings growth (Sales Growth: 4.51%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Mercury Labs a good stock for long-term investment?
Mercury Labs shows a 5-year Profit Growth of -0.82% and an ROE of 5.94%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.11 before investing in MERCURYLAB shares.
How does Mercury Labs compare with its industry peers?
Mercury Labs competes with major peers in the Pharmaceuticals. Investors should compare MERCURYLAB share price P/E of 20.79x and ROE of 5.94% against the industry averages to determine competitive standing.
What is the P/E ratio of MERCURYLAB and what does it mean?
MERCURYLAB share price has a P/E ratio of 20.79x compared to the industry average of 31.77x. Investors pay ₹21 for every ₹1 of annual earnings.
How is MERCURYLAB performing according to Bull Run's analysis?
MERCURYLAB has a Bull Run fundamental score of 38.6/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does MERCURYLAB belong to?
MERCURYLAB operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Mercury Labs share price.
What is Return on Equity (ROE) and why is it important for MERCURYLAB?
MERCURYLAB has an ROE of 5.94%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Mercury Labs generates profits from shareholders capital.
How is MERCURYLAB debt-to-equity ratio and what does it indicate?
MERCURYLAB has a debt-to-equity ratio of 0.11, which indicates conservative financing with low financial risk.
What is MERCURYLAB dividend yield and is it a good dividend stock?
MERCURYLAB offers a dividend yield of 0.41%, meaning you receive ₹0.41 annual dividend for every ₹100 invested in Mercury Labs shares.
How has MERCURYLAB share price grown over the past 5 years?
MERCURYLAB has achieved 5-year growth rates of: Sales Growth 5.57%, Profit Growth -0.82%, and EPS Growth -0.82%.
What is the promoter holding in MERCURYLAB and why does it matter?
Promoters hold 73.66% of MERCURYLAB shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Mercury Labs.
What is MERCURYLAB market capitalisation category?
MERCURYLAB has a market capitalisation of ₹102 crores, placing it in the Small-cap category.
How volatile is MERCURYLAB stock?
MERCURYLAB has a beta of N/A. A beta > 1 suggests the Mercury Labs stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is MERCURYLAB operating profit margin trend?
MERCURYLAB has a 5-year average Operating Profit Margin (OPM) of 11.70%, indicating the company's operational efficiency.
How is MERCURYLAB quarterly performance?
Recent quarterly performance shows Mercury Labs YoY Sales Growth of 4.51% and YoY Profit Growth of 228.00%.
What is the institutional holding pattern in MERCURYLAB?
MERCURYLAB has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Mercury Labs stock.